PLEASANTON, Calif.,
Oct. 15, 2014 /PRNewswire/ --
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based
mechanical circulatory support therapies to save, support and
restore failing hearts, today announced that it will report its
operating results for the third quarter of fiscal year 2014 on
Wednesday, November 5.
The company will hold a conference call to discuss its financial
results and operating activities, open to all interested parties,
at 1:30 p.m., Pacific Standard Time
(4:30 p.m., Eastern Standard Time),
Wednesday, November 5, hosted by
D. Keith Grossman, President and
Chief Executive Officer, and Taylor C.
Harris, Vice President and Chief Financial Officer.
The teleconference can be accessed by calling (719) 325-2445,
passcode 6219511. Please dial in 10-15 minutes prior to the
beginning of the call. The webcast will be available on the
Internet at http://edge.media-server.com/m/p/grfi2fd7/lan/en, or
http://www.thoratec.com.
A replay of the conference call will be available through
Wednesday, November 12, via
http://www.thoratec.com, or by telephone at (719) 457-0820,
passcode 6219511.
Thoratec is a world leader in therapies to address
advanced-stage heart failure. The company's products include
the HeartMate II® LVAS (Left Ventricular Assist Systems)
and Thoratec® VAD (Ventricular Assist Device) with more
than 20,000 devices implanted in patients suffering from heart
failure. Thoratec also manufactures the CentriMag® and
PediMag®/PediVAS® product lines. Thoratec is
headquartered in Pleasanton,
California. For more information, visit the company's
website at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are
registered trademarks of Thoratec Corporation and HeartMate III,
HeartMate PHP, PVAD, IVAD and Pocket Controller are trademarks of
Thoratec Corporation. CentriMag and PediMag are registered
trademarks of Thoratec LLC, and PediVAS is a registered trademark
of Thoratec Switzerland GmbH.
SOURCE Thoratec Corporation